Authors' objectives: Screening and treatment for prostate cancer is controversial and carries with it the potential for overdiagnosis and overtreatment, as many prostate cancers grow very slowly and affected men often die of other causes before prostate cancer becomes symptomatic. Therefore, in addition to the available risk stratification methods, there often remains uncertainty regarding the optimal treatment strategy for initial management of patients with localized prostate cancer. Additionally, the tumor tissue present in a needle biopsy specimen may not be accurately representative of the entire tumor, leading to the possibility of both overestimation and underestimation of risk for disease progression. Thus, a desire for increased precision in diagnosis and treatment recommendations has led to interest in evaluating biomarkers, allowing for a more personalized approach to management and treatment. The Oncotype DX Genomic Prostate Score (GPS) Assay is a tumor gene expression profile test developed to assist treatment decisions for prostate cancer. This report examines the published evidence regarding the Oncotype DX GPS Assay.

Project Status: Completed

Year Published: 2016

URL for published report: The report may be purchased from: http://www.hayesinc.com/hayes/crd/?crd=50406

English language abstract: An English language summary is available

Publication Type: Not Assigned

Country: United States

Organisation Name: HAYES, Inc.

Contact Address: 157 S. Broad Street, Suite 200, Lansdale, PA 19446, USA. Tel: 215 855 0615; Fax: 215 855 5218

Contact Name: saleinfo@hayesinc.com

Contact Email: saleinfo@hayesinc.com

Copyright: Winifred S. Hayes, Inc